Alli Sparks Reevaluation Of OTC Weight-Loss Indication
This article was originally published in The Tan Sheet
Executive Summary
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
You may also be interested in...
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1